112,500 Shares in CeriBell (NASDAQ:CBLL) Bought by Orbimed Advisors LLC

Orbimed Advisors LLC bought a new position in shares of CeriBell (NASDAQ:CBLL - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund bought 112,500 shares of the company's stock, valued at approximately $2,912,000. Orbimed Advisors LLC owned 0.31% of CeriBell as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the company. FMR LLC purchased a new stake in shares of CeriBell during the 4th quarter worth about $128,120,000. ABG WTT Global Life Science Capital Partners GP Ltd purchased a new position in CeriBell in the 4th quarter worth approximately $28,160,000. RA Capital Management L.P. purchased a new position in CeriBell in the 4th quarter worth approximately $21,340,000. Vanguard Group Inc. purchased a new position in CeriBell in the 4th quarter worth approximately $18,015,000. Finally, Board of Trustees of The Leland Stanford Junior University purchased a new position in CeriBell in the 4th quarter worth approximately $16,143,000.

CeriBell Stock Performance

Shares of CBLL traded up $0.38 during trading on Friday, reaching $17.97. The company's stock had a trading volume of 405,581 shares, compared to its average volume of 276,227. The company has a fifty day moving average of $17.50 and a two-hundred day moving average of $22.35. CeriBell has a twelve month low of $10.01 and a twelve month high of $32.75.

CeriBell (NASDAQ:CBLL - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.43) by $0.07. The business had revenue of $20.49 million during the quarter, compared to analyst estimates of $19.30 million. Analysts forecast that CeriBell will post -2.46 EPS for the current fiscal year.

Wall Street Analyst Weigh In

CBLL has been the subject of a number of analyst reports. Canaccord Genuity Group restated a "buy" rating and issued a $33.00 price target on shares of CeriBell in a report on Wednesday, February 26th. LADENBURG THALM/SH SH initiated coverage on CeriBell in a report on Friday, April 4th. They issued a "buy" rating and a $32.00 price target for the company. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, CeriBell presently has a consensus rating of "Buy" and an average target price of $32.50.

Insider Activity at CeriBell

In related news, CEO Xingjuan Chao sold 5,700 shares of the company's stock in a transaction that occurred on Thursday, April 17th. The stock was sold at an average price of $15.02, for a total transaction of $85,614.00. Following the sale, the chief executive officer now directly owns 746,451 shares of the company's stock, valued at approximately $11,211,694.02. This represents a 0.76% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In the last ninety days, insiders have sold 24,700 shares of company stock valued at $372,434. Corporate insiders own 20.10% of the company's stock.

CeriBell Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.